Annexon, Inc.
1400 Sierra Point Parkway
Building C, 2nd Floor
Brisbane
California
94005
United States
Tel: 650-822-5500
Website: http://annexonbio.com/
Email: info@annexonbio.com
About Annexon, Inc.
We’re passionate about bringing game-changing therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders.
CSO, Larry Mattheakis, Ph.D
CFO, Jennifer Lew
Company Ownership: Public
Stock Symbol: ANNX
Stock Exchange: NASDAQ
64 articles about Annexon, Inc.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - May 16, 2023
5/16/2023
Annexon, Inc. announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
5/8/2023
Annexon, Inc. reported first quarter 2023 financial results and highlighted recent progress across its portfolio of complement therapies.
-
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
4/11/2023
Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. ET.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - February 16, 2023
2/16/2023
Annexon, Inc. announced that it has granted equity inducement awards to four new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Jan 17, 2023
1/17/2023
Annexon, Inc. announced that it has granted an equity inducement award to Dean “Rick” Artis, Ph.D., chief scientific officer, under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
1/8/2023
Annexon, Inc. reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.
-
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - November 17, 2022
11/17/2022
Annexon, Inc. announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
11/3/2022
Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, reported third quarter 2022 financial results.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - October 18, 2022
10/18/2022
Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - September 16, 2022
9/16/2022
Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Aug 17, 2022
8/17/2022
Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
-
Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.
-
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
7/11/2022
Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the closing of its private placement, resulting in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses.
-
Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.
-
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
6/7/2022
Annexon, Inc. announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease.
-
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
6/2/2022
Annexon, Inc. announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.
-
Annexon Biosciences to Participate in Upcoming May 2022 Investor Conferences
5/5/2022
Annexon, Inc. announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:
-
Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.